论文部分内容阅读
目的:检测卵巢上皮细胞肿瘤中Sema3A的表达情况,并探讨其与临床病理间的关系,分析Sema3A检测在上皮性卵巢癌诊断中的作用。方法:收集80例卵巢肿瘤石蜡标本,采用免疫组织化学法对不同病理分级的卵巢上皮性肿瘤进行Sema3A检测,并用蛋白印迹法检测Sema3A在另8对新鲜良、恶性卵巢肿瘤组织中的表达变化。结果:免疫组织化学检测结果示,在上皮性卵巢癌(卵巢癌)、上皮性交界性肿瘤(交界性肿瘤)及上皮性良性肿瘤(良性肿瘤)中,Sema3A表达存在差异。卵巢癌中Sema3A的表达与其病理分级(r=-0.624;P<0.001)、组织分类(r=0.311;P=0.028)相关。病理分级(G1、G2、G3)与Sema3A的表达分级呈正相关,不同组织学分级间的Sema3A表达有显著差异(P<0.001);而不同组织学分类的卵巢癌(浆液性乳头状腺癌、子宫内膜样腺癌、透明细胞癌、黏液样腺癌)间Sema3A的表达亦有显著差异(P<0.05)。8对卵巢上皮性良、恶性肿瘤组织的蛋白印迹检测结果与免疫组织化学检测结果完全相符,卵巢良、恶性肿瘤中的Sema3A表达有显著差异(P<0.001)。结论:Sema3A在卵巢癌、卵巢交界性肿瘤及卵巢良性肿瘤中的表达呈明显递降趋势。卵巢癌中Sema3A的表达水平随肿瘤恶性程度增高而增高,表明Sema3A阳性表达在卵巢癌诊断中有一定价值,并可提示肿瘤的恶性程度。
OBJECTIVE: To detect the expression of Sema3A in ovarian epithelial neoplasms and to explore the relationship between Sema3A and clinical pathology. To analyze the role of Sema3A in the diagnosis of epithelial ovarian cancer. Methods: Seventy eight ovarian tumor paraffin specimens were collected. Sema3A was detected by immunohistochemistry in ovarian epithelial tumors of different pathological grades. The expression of Sema3A in 8 pairs of fresh benign and malignant ovarian tumors was detected by Western blotting. Results: The results of immunohistochemistry showed that the expression of Sema3A was different in epithelial ovarian cancer (ovarian cancer), epithelial borderline tumor (borderline tumor) and benign epithelial tumor (benign tumor). The expression of Sema3A in ovarian cancer correlated with its pathological grade (r = -0.624; P <0.001) and histological classification (r = 0.311; P = 0.028). There was a positive correlation between the pathological grade (G1, G2, G3) and the expression of Sema3A, the difference of Sema3A expression between different histological grades (P <0.001), while the histological classification of ovarian cancer (serous papillary adenocarcinoma, Endometrioid adenocarcinoma, clear cell carcinoma and mucinous adenocarcinoma. The expression of Sema3A was also significantly different (P <0.05). 8 The results of Western blotting of epithelial ovarian epithelial benign and malignant tumors were in good agreement with the results of immunohistochemistry. The expression of Sema3A in benign and malignant ovarian tumors was significantly different (P <0.001). Conclusion: The expression of Sema3A in ovarian cancer, borderline ovarian tumor and benign ovarian tumor showed a declining trend. The expression of Sema3A in ovarian cancer increased with the malignant degree of the tumor, indicating that the positive expression of Sema3A has some value in the diagnosis of ovarian cancer and may indicate the malignancy of the tumor.